Vpr.A3A chimera inhibits HIV replication
- PMID: 18057006
- DOI: 10.1074/jbc.M706436200
Vpr.A3A chimera inhibits HIV replication
Abstract
Several APOBEC3 proteins (A3F and A3G), that are cytidine deaminases restrict human immunodeficiency virus (HIV) replication in the absence of the viral infectivity factor (Vif) protein. However, Vif leads to their degradation and counteracts their effects. Another member, A3A, restricts some retrotransposons and another virus but not HIV. We reasoned that this failure was due to the lack of appropriate targeting. Thus, we fused A3A to another viral protein, Vpr, which binds p6 in Gag and is incorporated into viral cores. Indeed, the Vpr.A3A chimera but not A3A was found abundantly in the viral core. It also restricted potently the replication of HIV and simian immunodeficiency virus in the presence and absence of Vif. Because we identified a high frequency of G to A mutations in viral cDNAs, this antiviral activity was mediated by DNA editing. Interestingly, our fusion protein did not restrict murine leukemia virus, which does not incorporate Vpr. Thus, by targeting appropriately a potent single domain cytidine deaminase, we rendered HIV and simian immunodeficiency virus restriction resistant to Vif.
Similar articles
-
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.Retrovirology. 2007 Aug 29;4:61. doi: 10.1186/1742-4690-4-61. Retrovirology. 2007. PMID: 17727729 Free PMC article.
-
Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.PLoS One. 2008 Apr 16;3(4):e1995. doi: 10.1371/journal.pone.0001995. PLoS One. 2008. PMID: 18414671 Free PMC article.
-
APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.mBio. 2023 Aug 31;14(4):e0078223. doi: 10.1128/mbio.00782-23. Epub 2023 Aug 9. mBio. 2023. PMID: 37555667 Free PMC article.
-
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.J Mol Biol. 2014 Mar 20;426(6):1220-45. doi: 10.1016/j.jmb.2013.10.033. Epub 2013 Nov 2. J Mol Biol. 2014. PMID: 24189052 Free PMC article. Review.
-
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006. Trends Pharmacol Sci. 2009. PMID: 19837465 Free PMC article. Review.
Cited by
-
Conservation and Innovation of APOBEC3A Restriction Functions during Primate Evolution.Mol Biol Evol. 2016 Aug;33(8):1889-901. doi: 10.1093/molbev/msw070. Epub 2016 Apr 6. Mol Biol Evol. 2016. PMID: 27189538 Free PMC article.
-
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.PLoS Pathog. 2012;8(7):e1002800. doi: 10.1371/journal.ppat.1002800. Epub 2012 Jul 12. PLoS Pathog. 2012. PMID: 22807680 Free PMC article.
-
Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.RNA Biol. 2010 Nov-Dec;7(6):754-74. doi: 10.4161/rna.7.6.14115. Epub 2010 Nov 1. RNA Biol. 2010. PMID: 21160280 Free PMC article. Review.
-
The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection.J Virol. 2011 Nov;85(21):11361-71. doi: 10.1128/JVI.05046-11. Epub 2011 Aug 10. J Virol. 2011. PMID: 21835794 Free PMC article.
-
APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.J Mol Biol. 2014 Mar 20;426(6):1296-307. doi: 10.1016/j.jmb.2013.12.014. Epub 2013 Dec 17. J Mol Biol. 2014. PMID: 24361275 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials